Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia

Summary

This is a Phase I, open-label, dose escalation study of UCART123 administered intravenously to patients with newly diagnosed CD123 positive adverse genetic risk acute myeloid leukaemia (AML) defined in the ELN adverse genetic risk group (2017). The purpose of this study is to evaluate the safety and clinical activity of multiple infusions of UCART123 and to determine the Maximum Tolerated Dose (MTD).

Timeline

Start

2019-07-11

Primary completion

2019-12-05

Completion

2019-12-05

Outcome

Outcome not reported

Stopped: “The trial was discontinued due to sponsor's decision and not a consequence of any safety concern”

Drugs

Indications